Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
208,99 $
+0,00 $
0,00%
177,42 € 01:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,05%
Nachhaltigkeits-Score
54 %
Index-Zuordnung
S&P 500
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,05: MK4Z0E
Werbung

AbbVie News

13.10.25 - PR Newswire
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease PR Newswire
13.10.25 - PR Newswire
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors PR Newswire
09.10.25 - PR Newswire
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer PR Newswire
06.10.25 - PR Newswire
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor PR Newswire
02.10.25 - PR Newswire
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
AbbVie to Host Third-​Quarter 2025 Earnings Conference Call PR Newswire
01.10.25 wallstreetONLINE Redaktion
Aktien kräftig im Plus: Medikamenten-Deal entfesselt Pharma-Aktien
Die Aktienkurse großer US-​Pharmaunternehmen haben am Dienstag kräftig zugelegt, nachdem Präsident Donald Trump eine Vereinbarung mit Pfizer bekanntgab.Pfizer senkt ...
01.10.25 - PR Newswire
Natrelle® Awarded Supplier Agreement from Vizient
Natrelle® Awarded Supplier Agreement from Vizient PR Newswire
30.09.25 - PR Newswire
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S. PR Newswire
30.09.25 - PR Newswire
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-​Drug Conjugate (ADC) to Treat Rare Cancer with ...
29.09.25 - PR Newswire
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility PR Newswire
29.09.25 - PR Newswire
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-​gynx) PR Newswire
26.09.25 - PR Newswire
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease PR Newswire
25.09.25 - PR Newswire
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai PR Newswire
23.09.25 - PR Newswire
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality PR Newswire
17.09.25 - ARIVA.DE Redaktion
AbbVie-Aktie zum Einstieg bereit: Value-Perle mit 25 Prozent Potenzial
Der US-​Pharmakonzern AbbVie gehört zu den größten Playern der Branche und hat sich erfolgreich gegen den Patentablauf seines Blockbusters Humira gestemmt. Doch die ...
17.09.25 wallstreetONLINE Redaktion
Top-Aktien im Check: Novo, Eli Lilly oder doch eine ganz andere Aktie? Das sind Berenbergs Top-Picks
Forschungsinnovationen bei Immunologie und Adipositas-​Behandlungen sind in den vergangenen Jahren zu einem echten Gamechanger für die Pharmabranche geworden. ...
14.09.25 - ARIVA.DE Redaktion
Stabil und zuverlässig: Diese drei Dividendenaktien sind einfach zum Verlieben!
Dividendenaktien sind bei vielen Anlegerinnen und Anleger beliebt. Diese drei Werte bieten eine besonders hohe Qualität und sind (fast) zum Verlieben.
09.09.25 - PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories PR Newswire
05.09.25 - PR Newswire
AbbVie Declares Quarterly Dividend
AbbVie Declares Quarterly Dividend PR Newswire
03.09.25 - PR Newswire
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory ...

Newssuche

Videos

newspaper
16.04.26 +0,05%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »